View of Subcutaneous infliximab in the treatment of refractory Crohn‘s disease patients – a pilot study of drug immunogenicity

Return to Article Details Subcutaneous infliximab in the treatment of refractory Crohn‘s disease patients – a pilot study of drug immunogenicity